Pell Bio-Med Technology Co., Ltd. (6949)

Overview

PELL Bio-Med Technology Co., Ltd. is a pioneering biomedical company founded in 2017 and headquartered in Taipei, Taiwan. The company specializes in the development of advanced cell culture technologies and techniques with a primary focus on therapeutic applications. It is at the forefront of creating innovative approaches for regenerative medicine and cancer treatment through its research and development in cell immunotherapy, stem cell regenerative therapy, and various cancer medicines. PELL Bio-Med Technology aims to revolutionize the medical field by offering cutting-edge solutions for pressing health issues, integrating modern biotechnology with medical science to improve patient outcomes.

Products and Services

• Good Tissue Practice Laboratory Infrastructure
  

  PELL Bio-Med Technology provides state-of-the-art laboratory infrastructure that meets good tissue practice standards, ensuring that the cell culture and tissue processing are conducted in an environment that maximizes safety and efficacy for therapeutic use.

• Adipose-Derived Stem Cells (ADSC) for Regenerative Medicine
  

  The company leverages adipose-derived stem cells (ADSC) for the creation of treatments in regenerative medicine, capitalizing on their potential to repair or replace damaged tissues and organs, thus opening new avenues for treating chronic diseases and injuries.

• CIK and DC-CIK against Cancers
  

  PELL Bio-Med Technology is involved in the development and commercialization of Cytokine-Induced Killer (CIK) and Dendritic Cell-Cytokine Induced Killer (DC-CIK) cells as innovative therapeutic options for targeting and treating various forms of cancer through immunotherapy.

• Chimeric Antigen Receptor T Cell (CAR-T), CAR-NK, and CAR-?dT
  

  The company is at the cutting edge of developing chimeric antigen receptor technologies, including CAR-T cells, CAR-Natural Killer (NK) cells, and CAR-?dT cells, representing a promising new generation of cancer treatments that reengineer the body’s own cells to fight cancer more effectively.

• Gene-Modified ADSC
  

  By genetically modifying adipose-derived stem cells, PELL Bio-Med Technology enhances their therapeutic potential, paving the way for novel treatments in regenerative medicine and for combating various diseases.

• Products for B-NHL, Ovarian Cancer, Multiple Myeloma, and Thyroid Cancer
  

  PELL Bio-Med Technology is developing targeted treatments for a range of cancer indications, including B-Cell Non-Hodgkin's Lymphoma (B-NHL), ovarian cancer, multiple myeloma, and thyroid cancer, focusing on improving outcomes and quality of life for patients fighting these diseases.